A meta-analysis seeks to determine if adding hormone therapy to radiotherapy after prostatectomy improves overall survival.

Recent research has put a spotlight on a number of factors which could be used to estimate which patients with nonmetastatic, unfavorable-risk prostate cancer are at high risk for a shorter time until ...

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

The recurrence of prostate cancer can now be detected 14.8 months sooner than existing clinical practices with new technology developed by a professor at Purdue University in West Lafayette, Ind. The ...

At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...

Adding apalutamide to androgen deprivation therapy prolonged prostate-specific antigen progression-free survival in patients with biochemically recurrent prostate cancer in the phase 3 PRESTO trial.

More than 70% of patients with biochemically recurrent prostate cancer remained metastasis-free 5 years after PSMA PET/CT-guided salvage radiation therapy. Whole-pelvis radiation significantly ...

A Purdue University mechanical engineer and his international collaborators have developed a patent-pending method and algorithm to predict the recurrence of prostate cancer in patients treated by ...

In the article that accompanies this editorial, Aggarwal et al 8 found that 1 year of intensified androgen deprivation therapy (ADT) prolongs the time to next prostate-specific antigen progression (or ...

Longer time to relapse is associated with a decreased risk of dying from prostate cancer. PSA recurrence (PSAR) more than five years after radical prostatectomy for prostate cancer is associated with ...